Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review
NHSC
Record ID 32004000895
English
Authors' objectives:
This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severe psoriatic arthritis.
Authors' recommendations:
Adalimumab (Humira) is a fully human anti-TNF-a monoclonal antibody in phase III trials for reducing the signs and symptoms of active psoriatic arthritis (PsA) in adults. It is anticipated that adalimumab will be administered by subcutaneous injection once a fortnight at a dose of 40mg. There are currently no published abstracts or results of clinical trials in psoriatic arthritis. Adalimumab is currently licensed for use in rheumatoid arthritis, and is in phase III trials for juvenile idiopathic arthritis, ankylosing spondylitis, chronic-plaque psoriasis and Crohns disease.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
- Arthritis, Psoriatic
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.